- Report
- October 2024
- 193 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- March 2025
- 359 Pages
Global
From €5201EUR$5,450USD£4,358GBP
- Report
- March 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- March 2025
- 175 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- March 2025
- 140 Pages
Global
From €2862EUR$2,999USD£2,398GBP
- Report
- May 2024
- 129 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 138 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 134 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Clinical Trials
- June 2024
- 60 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Report
- January 2025
- 880 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- June 2024
- 200 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- August 2024
- 150 Pages
Global
From €2662EUR$2,789USD£2,230GBP
- Report
- January 2025
- 180 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- June 2020
- 753 Pages
Global
From €3149EUR$3,300USD£2,639GBP
- Report
- February 2024
- 110 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- January 2022
- 114 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- August 2018
- 25 Pages
Global
From €9544EUR$10,000USD£7,996GBP
- Report
- September 2024
- 93 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- April 2023
- 108 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- March 2025
- 50 Pages
Global
From €2529EUR$2,650USD£2,119GBP

Erlotinib is an oncology drug used to treat certain types of cancer, such as non-small cell lung cancer, pancreatic cancer, and head and neck cancer. It is a tyrosine kinase inhibitor, meaning it works by blocking the action of certain proteins that are involved in the growth and spread of cancer cells. Erlotinib is taken orally and is usually prescribed in combination with other cancer treatments. Common side effects include nausea, diarrhea, rash, and fatigue.
Erlotinib is a widely used drug in the oncology market, with many generic and branded versions available. It is approved by the US Food and Drug Administration (FDA) and is available in many countries around the world.
Some companies in the Erlotinib market include AstraZeneca, Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more